Robert Menendez actually said...

"PBMs benefit significantly from high list prices and have no incentive to choose lower-priced drugs to drive down patient costs."

"Under the current structure, PBMs make more money when a drug's list price increases, while patients bear the financial burden."

"Pharmacy benefit managers are key players, or should be, in alleviating patients' financial burden at the pharmacy counter."

"Would patients be better off if PBMs and other supply chain entities were paid flat fees for the services they provide?"